Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report

Immune checkpoint inhibitors (ICIs) have greatly transformed the treatment and improved the prognosis for patients with non-small cell lung cancer (NSCLC) without driver gene alterations. However, the effects of ICI combination therapy in ROS1 fusion-positive NSCLC remains unclear. Herein, we presen...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Ningning, Huang, Siyuan, Li, Linlin, Guo, Qianqian, Geng, Di, Zhang, Huixian, Guo, Sanxing, Li, Xingya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500430/
https://www.ncbi.nlm.nih.gov/pubmed/36160430
http://dx.doi.org/10.3389/fphar.2022.898623
_version_ 1784795219888177152
author Yan, Ningning
Huang, Siyuan
Li, Linlin
Guo, Qianqian
Geng, Di
Zhang, Huixian
Guo, Sanxing
Li, Xingya
author_facet Yan, Ningning
Huang, Siyuan
Li, Linlin
Guo, Qianqian
Geng, Di
Zhang, Huixian
Guo, Sanxing
Li, Xingya
author_sort Yan, Ningning
collection PubMed
description Immune checkpoint inhibitors (ICIs) have greatly transformed the treatment and improved the prognosis for patients with non-small cell lung cancer (NSCLC) without driver gene alterations. However, the effects of ICI combination therapy in ROS1 fusion-positive NSCLC remains unclear. Herein, we present a case with ROS1 fusion-positive NSCLC treated with ICI plus chemotherapy. The patient achieved a continuous partial response (PR) to ICI plus chemotherapy and a more than 35 months progression free survival. This case demonstrates that ICI plus chemotherapy is a promising option for patients with ROS1 fusion-positive NSCLC.
format Online
Article
Text
id pubmed-9500430
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95004302022-09-24 Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report Yan, Ningning Huang, Siyuan Li, Linlin Guo, Qianqian Geng, Di Zhang, Huixian Guo, Sanxing Li, Xingya Front Pharmacol Pharmacology Immune checkpoint inhibitors (ICIs) have greatly transformed the treatment and improved the prognosis for patients with non-small cell lung cancer (NSCLC) without driver gene alterations. However, the effects of ICI combination therapy in ROS1 fusion-positive NSCLC remains unclear. Herein, we present a case with ROS1 fusion-positive NSCLC treated with ICI plus chemotherapy. The patient achieved a continuous partial response (PR) to ICI plus chemotherapy and a more than 35 months progression free survival. This case demonstrates that ICI plus chemotherapy is a promising option for patients with ROS1 fusion-positive NSCLC. Frontiers Media S.A. 2022-09-09 /pmc/articles/PMC9500430/ /pubmed/36160430 http://dx.doi.org/10.3389/fphar.2022.898623 Text en Copyright © 2022 Yan, Huang, Li, Guo, Geng, Zhang, Guo and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Yan, Ningning
Huang, Siyuan
Li, Linlin
Guo, Qianqian
Geng, Di
Zhang, Huixian
Guo, Sanxing
Li, Xingya
Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report
title Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report
title_full Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report
title_fullStr Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report
title_full_unstemmed Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report
title_short Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report
title_sort case report: durable response to immuno-chemotherapy in a case of ros1 fusion-positive advanced lung adenocarcinoma: a case report
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500430/
https://www.ncbi.nlm.nih.gov/pubmed/36160430
http://dx.doi.org/10.3389/fphar.2022.898623
work_keys_str_mv AT yanningning casereportdurableresponsetoimmunochemotherapyinacaseofros1fusionpositiveadvancedlungadenocarcinomaacasereport
AT huangsiyuan casereportdurableresponsetoimmunochemotherapyinacaseofros1fusionpositiveadvancedlungadenocarcinomaacasereport
AT lilinlin casereportdurableresponsetoimmunochemotherapyinacaseofros1fusionpositiveadvancedlungadenocarcinomaacasereport
AT guoqianqian casereportdurableresponsetoimmunochemotherapyinacaseofros1fusionpositiveadvancedlungadenocarcinomaacasereport
AT gengdi casereportdurableresponsetoimmunochemotherapyinacaseofros1fusionpositiveadvancedlungadenocarcinomaacasereport
AT zhanghuixian casereportdurableresponsetoimmunochemotherapyinacaseofros1fusionpositiveadvancedlungadenocarcinomaacasereport
AT guosanxing casereportdurableresponsetoimmunochemotherapyinacaseofros1fusionpositiveadvancedlungadenocarcinomaacasereport
AT lixingya casereportdurableresponsetoimmunochemotherapyinacaseofros1fusionpositiveadvancedlungadenocarcinomaacasereport

Ejemplares similares